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Abstract
Human polyomaviruses are known to cause persistent or latent infections, which are reactivated
under immunosuppression. Polyomaviruses have been found to immortalize cell lines and to
possess oncogenic properties. Moreover, the recently discovered Merkel cell polyomavirus shows
a strong association with human Merkel cell carcinomas. Another novel human polyomavirus, WU
polyomavirus (WUPyV), has been identified in respiratory specimens from patients with acute
respiratory tract infections (ARTI). WUPyV has been proposed to be a pathogen in ARTI in early
life and immunocompromised individuals, but so far its role as a causative agent of respiratory
disease remains controversial.
The objective of our study was to determine the prevalence of WUPyV infections in adult
hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease (COPD)
and to establish its potential clinical relevance by comparison to patients with stable COPD
hospitalized for other reasons than acute exacerbation of COPD (AE-COPD).
A total of 378 respiratory specimens, each 189 induced sputum and nasal lavage samples from 189
patients, who had been recruited in a prospective 2:1 ratio case-control set-up between 1999 and
2003, were evaluated for the presence of WUPyV DNA by real-time PCR.
In the present study we could not detect WUPyV DNA in 378 respiratory specimens from 189
adult hospitalized patients with AE-COPD and stable COPD in four consecutive years.
Persistence of viral replication or reactivation of latent WUPyV infection did not occur. WUPyV
may not play a major role in adult immunocompetent patients with AE-COPD and stable COPD.
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Polyomaviruses are small, non-enveloped viruses with a
circular double-stranded DNA genome of approximately
5,000 base pairs. They are known to be capable of immor-
talizing animal and human cell lines. Their oncogenic
potential has been demonstrated in vitro and in various
animal cancer models and is accomplished by the integra-
tion of viral DNA into the host cell genome. Expression of
the viral T-antigen is mandatory for cell transformation
[1]. In the last years there has been a re-emergence of
interest in human polyomaviruses as possible carcinogens
as three novel polyomaviruses have been described in
humans. While KI and WU polyomavirus have initially
been detected in respiratory specimens [2,3], the Merkel
cell polyomavirus (MCPyV) was observed to be clonally
integrated into Merkel cell carcinomas (MCC), a rare but
aggressive human skin cancer of neuroendocrine origin
[4]. Meanwhile, MCPyV has also been described in respi-
ratory specimens [5,6], small cell lung cancer tissue [7],
and there is increasing evidence for a strong association
between MCPyV and MCC [8-12]. Recently a first study
reported the detection of KIPyV DNA in lung cancer spec-
imens [13], and many more studies targeting different
human polyomaviruses, cancer entities and populations
may be anticipated in the near future. However, the detec-
tion in the respiratory tract is not a unique feature of KI-,
MC- and WUPyV and transmission by the respiratory
route has already been suggested for the first two human
polyomaviruses, BK and JC virus [14-16]. In 2007, WU
polyomavirus (WUPyV) was identified in respiratory
specimens from patients with acute respiratory tract infec-
tions (ARTI) [2]. It has been proposed to be a relevant
pathogen in ARTI in early life and immunocompromised
individuals, but so far its role as a causative agent of respi-
ratory disease remains controversial as it was also found
in healthy asymptomatic individuals [17,18]. WUPyV
infections appear endemic worldwide [2], detection fre-
quencies vary from 0.4% [19] to 7% [20] and coinfections
with other respiratory viruses are common [21].
The aim of the present study was to determine the preva-
lence of WUPyV infections in adult hospitalized patients
with acute exacerbation of chronic obstructive pulmonary
disease (COPD) and to establish its potential clinical rel-
evance by comparison to patients with stable COPD hos-
pitalized for other reasons than acute exacerbation of
COPD (AE-COPD).
A total of 378 respiratory specimens, each 189 induced
sputum and nasal lavage samples from 189 patients were
retrospectively evaluated for the presence of WUPyV DNA.
Subjects with AE-COPD and stable COPD had been
recruited in a prospective case-control study in a 2:1 ratio
between October 1999 and April 2003. Underlying crite-
ria, definitions and procedures have been the same as
described previously [22]. Notably, patients with thoracic
malignancies were excluded from the study. The induced
sputum and nasal lavage samples were neatly stored in
aliquots at -70°C until further processing. DNA was
extracted from the samples using the QIAamp DNA Blood
Mini Kit (Qiagen, Hilden, Germany) and stored at -20°C
for further testing. Although the amplifiability of the
assayed sample DNA was recently demonstrated by the
detection of another novel respiratory agent, the human
bocavirus [23], the human β-globin gene was amplified as
a cellular gene on a LightCycler PCR platform (LightCy-
cler® Control Kit DNA, Roche, Mannheim, Germany) in
order to demonstrate the integrity and sufficient quality of
DNA in the assayed specimens. Primers and probe for the
WUPyV real-time PCR assay were selected from the highly
conserved C-terminal region of the large T-antigen that
has been used for a qualitative WUPyV PCR previously
[24]. Blasting of primer and probe sequences against Gen-
Bank excluded significant homologies with other organ-
isms. The real-time PCR was performed in a final volume
of 25 μl consisting of 5 μl of extracted DNA, the primers
WU2958s (CCTGTTAGTGATTTTCACCCATGTA) and
WU2865a (TGTCAGCAAATTCAGTAAGGCCTATATAT) at
a final concentration of 400 nM, the probe WU2925s-TM
(6FAM-AAAGTTGTGTATTGGAAAGAACTGTTAGACA-
TAMRA) at a final concentration of 100 nM, and 1×
Quantitect probe master mix (Qiagen, Hilden, Germany)
as described previously [25]. The cycling conditions were
50 cycles with 30 s at 95°C and 60 s at 60°C after a pre-
heating step of 15 min at 95°C. A plasmid containing the
PCR product obtained with the primers AG0048 and
AG0049 [2] cloned into the vector pCR2.1-TOPO (Invit-
rogen, Karlsruhe, Germany) was used as positive control
and for the standard curve. Strict laboratory procedures
were implemented to prevent PCR contamination. One
negative control was amplified for every five samples.
Plasmid spiking experiments were conducted in order to
exclude PCR inhibition by induced sputum and nasal lav-
age samples. Data analysis was performed using SPSS, ver-
sion 11.5 (SPSS Inc., Chicago, Illinois). Categorical data
were compared by Pearson's chi-squared or Fisher's exact
test, where appropriate. Normal distribution in continu-
ous variables was determined with the Kolmogorov-Smir-
nov test and differences were subsequently determined
either with the student's t-test or the Mann-Whitney-U
test. All p values were calculated two-sided with statistical
significance set to p < 0.05. The study was approved by the
ethics committee of the Ruhr University, Bochum, Ger-
many. All study participants gave their written informed
consent prior to study inclusion.
The standard curve was linear over the range from 1+E01
to at least 1+E08 copies per reaction. Spiking experiments
using various dilutions of plasmid DNA that were incu-
bated with fresh lower respiratory tract patient samplesPage 2 of 5
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detection of the applied real-time PCR assay was deter-
mined to ten copies per reaction corresponding to 400
copies per mL of starting material. A total of 378 respira-
tory specimens, each 189 induced sputum and nasal lav-
age samples, from 189 adult hospitalized COPD patients
were investigated for the presence of WUPyV DNA by
quantitative real-time PCR. Of those, 123 patients
(65.1%) had an acute exacerbation of COPD (AE-COPD)
and 66 (34.9%) had stable COPD. The demographic and
clinical characteristics of the study population with regard
to the COPD status are shown in Table 1. The two groups
were comparable in terms of age, sex, body mass index,
smoking behavior, pack years and medication. Spiromet-
ric data before discharge were available for 77 of 123
patients (62.6%) with AE-COPD, had significantly
improved after treatment for acute exacerbation and were
comparable to the baseline airflow in the control group.
Significant differences were apparent for increased airflow
limitation on admission, higher C-reactive protein levels
and leukocyte counts in the AE-COPD group (Table 1).
WUPyV DNA was not detected in any of the tested sam-
ples when using a sensitive real-time PCR assay.
Our findings are in agreement with two recent studies
from China [26] and the UK [27], which failed to detect
WUPyV DNA in immunocompetent adults. The initial
investigation by Gaynor et al. found four adults with
altered immune status or multiple comorbidities to be
positive for WUPyV [2]. None of the mentioned studies
explicitly included patients with AE-COPD or stable
COPD. The present population consisted of predomi-
nantly elderly COPD patients with severely impaired lung
function and concomitant low dose oral steroid medica-
tion. In a previous study performed on a comparable pop-
ulation we demonstrated that AE-COPD was significantly
associated with the detection of common respiratory
viruses, foremost human rhinovirus, influenza virus A
and respiratory syncytial virus, and that induced sputum
had a higher viral yield than upper respiratory tract speci-
mens in patients with AE-COPD [22]. Though our plas-
mid spiking experiments showed that PCR reactions were
not inhibited by the assayed specimens, the use of diluted
Table 1: Demographic and clinical characteristics of the study population
Variables All AE-COPD Stable COPD P valuea
n % n %d n %d
Patients 189 100 123 65.1 66 34.9
n %e n %e n %e
Sex 0.35
Female 39 20.6 28 22.8 11 16.7
Male 150 79.4 95 77.2 55 83.3
Smoking behavior 0.34
Active smokers 53 28.0 32 26.0 21 31.8
Non-smoker 26 13.8 20 16.3 6 9.1
Ex-smoker 110 58.2 71 57.7 39 59.1
Oral steroid medication 0.52
Yes 127 67.2 85 69.1 42 63.6
No 62 32.8 38 30.9 24 36.4
Inhaled corticosteroids 0.63
Yes 126 66.7 80 65.0 46 69.7
No 63 33.3 43 35.0 20 30.3
Mean SD Mean SD Mean SD
Age (years) 67 10 68 9 65 11 0.17
Body mass index (kg/m2) 26.9 5.1 26.8 5.0 27.2 5.2 0.60
Median Range Median Range Median Range
Pack yearsb 30 21-20 30 21-20 30 21-20 0.71
FEV1ad (L) 1.0 0.4-2.6 1.0 0.4-2.2 1.2 0.5-2.6 < 0.0001
FEV1ad (% predicted) 38.0 16.7-79.0 36.7 16.7-79.0 42.9 19.4-77.3 0.003
FEV1dis (L) 1.2 0.5-2.9 1.2 0.6-2.9 1.2 0.5-2.6 0.53
FEV1dis (% predicted) 43.6 18.5-78.9 44.3 18.5-78.9 42.9 19.4-77.3 0.90
CRP (mg/dL) 0.8 0.0-39.8 1.0 0.0-39.8 0.6 0.0-12.9 0.0002
Leukocytes/nL 10.5 0.7-27.2 10.9 0.7-27.2 10.1 5.1-24.0 0.016
Oral steroid dose (mg)c 7.5 0-150 10 0-150 5 0-150 0.098
Notes: a P values with statistical significance are printed bold. b Pack years in active and ex-smokers. c Oral steroid dose in prednisone equivalent 
before admission. dPercent in line. e Percent in column. Abbreviations: (AE-)COPD = (acute exacerbation of) chronic obstructive pulmonary 
disease. CRP = C-reactive protein. FEV1ad = forced expiratory volume in one second on admission. FEV1dis = baseline forced expiratory volume in 
one second for the control group and before discharge after recovery from exacerbation for the AE-COPD group. SD = standard deviation.Page 3 of 5
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and for the generation of the standard curve is an inevita-
ble limitation of the present study. Infectious WU polyo-
mavirus has yet to be isolated and cell lines susceptible to
infection still need to be identified [28]. However, in the
present study we could not detect WUPyV DNA in 378 res-
piratory specimens from 189 adult hospitalized patients
with AE-COPD and stable COPD in four consecutive years
between 1999 and 2003, whereas recent reports found
WUPyV circulating in German, predominantly pediatric
populations within and beyond our study period
[24,25,29].
Our findings support the hypothesis that primary WUPyV
infection is acquired in early life rather than adulthood
and suggest that persistence of viral replication or reacti-
vation of latent WUPyV infection is not a common phe-
nomenon in the adult COPD population. Hence, WUPyV
may not play a major role in adult immunocompetent
patients with AE-COPD and stable COPD. A clear linkage
between WUPyV and human disease still remains to be
determined.
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